Jalra-M 50mg/850mg Tablet is a fixed-dose combination medication containing Metformin 850mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The synergistic effect of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects of type 2 diabetes. Jalra-M is prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on monotherapy. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated but may rarely cause hypersensitivity reactions. Jalra-M should be used cautiously in patients with hepatic impairment and contraindicated in those with severe renal dysfunction. Regular monitoring of blood glucose levels and adherence to prescribed dosage are critical for optimal therapeutic outcomes.